CEA is used to monitor disease recurrence and therapeutic efficacy in colorectal cancer and gynecologic cancer such as endometrial cancer, ovarian cancer, cervical cancer, and vulvar cancer [20–26]. The gene discussed is CEACAM5; the disease is ovarian cancer.